Phase II study of tarceva as third-line treatment in advanced non-small cell lung cancer

被引：0
|
作者：
de Castro, Javier
Pallares, Cinta
Gurpide, Alfonso
Cobo, Manuel
Paz-Ares, Luis
Gonzalez-Larriba, Jose Luis
Insa, Amelia
Domine, Manuel
Sanchez, Rocio
Massuti, Bartomeu
机构：
[1] Hosp La Paz, E-28040 Madrid, Spain
[2] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[3] Clin Univ Navarra, E-03080 Pamplona, Spain
[4] Hosp Carlos Haya, Malaga, Spain
[5] Hosp Univ Doce Octobre, Madrid, Spain
[6] Hosp Clin San Carlos, Madrid, Spain
[7] Hosp Clin, Valencia, Spain
[8] Fdn Jimenez Diaz, Madrid, Spain
[9] Roche Farma Espana, Oncol Unit, Madrid, Spain
[10] Gen Hosp Univ Alicante, Alicante, Spain
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：236 / 236
页数：1
相关论文
共 50 条
  • [1] Third-line therapy in advanced non-small cell lung cancer
    Geng, Zhen Ying
    Jiao, Shun Chang
    Liu, Shi Cui
    Li, Ying
    Liu, Zhe Feng
    Zhang, Guo Qing
    Wang, Li Jie
    Qu, Feng
    [J]. JOURNAL OF BUON, 2013, 18 (04): : 899 - 907
  • [2] A phase II study of enzastaurin as second- or third-line treatment of non-small cell lung cancer (NSCLC)
    Bepler, G.
    Oh, Y.
    Burris, H.
    Cleverly, A.
    Lahn, M.
    Herbst, R. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] A phase II study of enzastaurin as second- or third-line treatment of non-small cell lung cancer (NSCLC)
    Oh, Y.
    Herbst, R.
    Burris, H.
    Cleverly, A.
    Lahn, M.
    Bepler, G.
    [J]. EJC SUPPLEMENTS, 2006, 4 (12): : 35 - 35
  • [4] Retrospective analysis of third-line chemotherapy in advanced non-small cell lung cancer
    Tatli, Ali Murat
    Arslan, Deniz
    Uysal, Mukremin
    Goksu, Sema Sezgin
    Gunduz, Seyda Gulenay
    Coskun, Hasan Senol
    Ozdogan, Mustafa
    Savas, Burhan
    Bozcuk, Hakan Sat
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (04) : 805 - 809
  • [5] Efficacy and Toxicity of Third-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer
    Beninato, T.
    Manglaviti, S.
    Zattarin, E.
    Apollonio, G.
    Galli, E.
    Bini, M.
    Sposetti, C.
    Massa, G.
    Bottiglieri, A.
    Ganzinelli, M.
    Proto, C.
    Ferrara, R.
    Prelaj, A.
    Galli, G.
    De Toma, A.
    Brambilla, M.
    Occhipinti, M.
    De Braud, F. G. M.
    Garassino, M. C.
    Lo Russo, G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1078 - S1078
  • [6] Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study
    Hoang, Tien
    Campbell, Toby C.
    Zhang, Chong
    Kim, KyungMann
    Kolesar, Jill M.
    Oettel, Kurt R.
    Blank, Jules H.
    Robinson, Emily G.
    Ahuja, Harish G.
    Kirschling, Ron J.
    Johnson, Peter H.
    Huie, Michael S.
    Wims, Mary E.
    Larson, Martha M.
    Hernan, Hilary R.
    Traynor, Anne M.
    [J]. INVESTIGATIONAL NEW DRUGS, 2014, 32 (01) : 195 - 199
  • [7] Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study
    Tien Hoang
    Toby C. Campbell
    Chong Zhang
    KyungMann Kim
    Jill M. Kolesar
    Kurt R. Oettel
    Jules H. Blank
    Emily G. Robinson
    Harish G. Ahuja
    Ron J. Kirschling
    Peter H. Johnson
    Michael S. Huie
    Mary E. Wims
    Martha M. Larson
    Hilary R. Hernan
    Anne M. Traynor
    [J]. Investigational New Drugs, 2014, 32 : 195 - 199
  • [8] Efficacy and Toxicity of Pemetrexed as a Third-line Treatment for Non-small Cell Lung Cancer
    Sun, Jong-Mu
    Lee, Keun-Wook
    Kim, Jee Hyun
    Kim, Yu Jung
    Yoon, Ho Il
    Lee, Jae-Ho
    Lee, Choon-Taek
    Lee, Jong Seok
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (01) : 27 - 32
  • [9] Biological predictors of third-line treatment outcomes in patients with advanced non-small cell lung cancer.
    Vassias, Antonios
    Vassos, Dimitrios
    Grapsa, Dimitra
    Bakakos, Petros
    Rovina, Nikoletta
    Syrigos, Konstantinos N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer
    de Marinisa, Filippo
    Grossi, Francesco
    [J]. ONCOLOGIST, 2008, 13 : 14 - 20
12345